Citable company snapshot
West Pharmaceutical Services's latest SEC-sourced 2026-03-31 period shows $844.90M in revenue and $138.80M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $844.90M | $805.00M | +5.0% |
| xbrl:GrossProfit | Mar 31, 2026 | $296.40M | $303.90M | -2.5% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $177.10M | $156.60M | +13.1% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $138.80M | $132.10M | +5.1% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $89.90M | $251.10M | -64.2% |
| Free Cash Flow (computed) | Mar 31, 2026 | $47.20M | $175.00M | -73.0% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed Apr 23, 2026; accession 0000105770-26-000049.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
